Kimelman & Baird’s Gilead Sciences GILD Stock Holding History

Kimelman & Baird’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3K	Hold	200	–	–	﹤0.01%	200
2026 Q1	$27.9K	Hold	200	–	–	﹤0.01%	196
2025 Q4	$24.5K	Hold	200	–	–	﹤0.01%	204
2025 Q3	$22.2K	Hold	200	–	–	﹤0.01%	223
2025 Q2	$22.2K	Hold	200	–	–	﹤0.01%	234
2025 Q1	$22.4K	Hold	200	–	–	﹤0.01%	232
2024 Q4	$18.5K	Hold	200	–	–	﹤0.01%	240
2024 Q3	$16.8K	Hold	200	–	–	﹤0.01%	245
2024 Q2	$13.7K	Buy	+200	New	+$13.3K	﹤0.01%	256
2017 Q4	–	Sell	-2,550	Closed	-$207K	–	119
2017 Q3	$207K	Buy	+2,550	New	+$195K	0.03%	114
2016 Q4	–	Sell	-2,550	Closed	-$202K	–	120
2016 Q3	$202K	Hold	2,550	–	–	0.04%	100
2016 Q2	$213K	Buy	2,550 +50	+2%	+$4.44K	0.04%	94
2016 Q1	$230K	Sell	2,500 -17	-0.7%	-$1.53K	0.04%	100
2015 Q4	$255K	Buy	+2,517	New	+$262K	0.05%	93
2015 Q2	$293K	Hold	2,500	–	–	0.05%	98
2015 Q1	$245K	Hold	2,500	–	–	0.04%	102
2014 Q4	$236K	Hold	2,500	–	–	0.04%	105
2014 Q3	$266K	Hold	2,500	–	–	0.05%	99
2014 Q2	$207K	Buy	+2,500	New	+$195K	0.04%	108

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kimelman & Baird's GILD Position: Q2 2026 in Review

Kimelman & Baird held its Gilead Sciences (GILD) position steady in Q2 2026 at 200 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #200.

Kimelman & Baird first reported a position in GILD in Q2 2014 and has held it in 19 quarters since. The position peaked at $293K in Q2 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Kimelman & Baird held 200 shares of Gilead Sciences worth $25.3K as of Q2 2026.
Kimelman & Baird left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up ﹤0.01% of Kimelman & Baird's portfolio in Q2 2026, its #200 holding.
Kimelman & Baird first reported a position in Gilead Sciences in Q2 2014 and has held it in 19 quarters since.
Kimelman & Baird's Gilead Sciences position peaked at $293K in Q2 2015.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Kimelman & Baird's 13F filing for Q2 2026, filed 5 Aug 2026.